anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To determine the feasibility of a combined therapeutic yoga and resistance exercise intervention for lung cancer survivors and their caregivers. A single group before and after intervention study design will be used for this pilot feasibility trial. Brochures and information about the study will be distributed at the Cross Cancer Institute, and interested individuals will be screened for eligibility. A convenient sampling technique will be used to recruit individuals with lung cancer and their caregiver. Participants deemed eligible to take part in the study will provide written informed consent to participate in the study and will undergo baseline testing. The intervention will be carried out over a period of 8 weeks. The feasibility outcomes will include eligibility rate, completion rate, adherence rate and adverse events. Dyspnea will be the primary self-reported outcome to be measured for individuals with lung cancer. The secondary outcomes will include fatigue, shoulder range of motion, chest expansion, and muscular strength. The outcome measures for the caregivers will include quality of life (QoL) and muscular strength.
The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value \>99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
BACKGROUND: Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are a spectrum of disease causing the nephrotic syndrome (NS), characterised by proteinuria with debilitating oedema, as well as a high risk of venous thromboembolic disease and infection. Untreated, 50-60% patients with FSGS progress to end stage kidney disease after 5 years. These diseases respond to immunosuppression with high dose glucocorticoids, but 75% will relapse as the glucocorticoids are withdrawn, leading to significant morbidity associated with prolonged use. In children, the B cell depleting monoclonal antibody rituximab reduces relapse risk, but this drug has not been tested in randomised controlled trial in adults.
METHODS: 130-150 adults with new or relapsing MCD/FSGS, from UK Renal Units, are being randomised to receive either rituximab (two 1 g infusions two weeks apart) or placebo. Partipicipants are recruited when they present with nephrosis, and all are treated with glucocorticoids as per KDIGO guidelines. Once in remission, prednisolone is withdrawn according to a pre-specified regimen. If in remission at 6 months, participants receive a further dose of trial drug. If they relapse, they are unblinded, and if they have received placebo, they are offered open label rituximab with protocolised prednisolone as in the main phase of the trial. The primary end point is time from remission to relapse. A number of secondary endpoints will be assessed including the effect of rituximab on: (1) NHS and societal resource use and hence cost: (2) safety: (3) other measures of efficacy, such as achievement of partial and complete remission of NS and the preservation of renal function: (4) health status of participant.
TRIAL REGISTRATION: TURING received ethical approval on 14 Jun 2019 - REC reference: 19/LO/0738. It is registered on EudraCT, with ID number: 2018-004611-50, with a start date of 2019-06-14.
The invention relates to an atorvastatin calcium composition tablet for treating hypercholesteremia, belonging to the technical field of medicines. The tablet is prepared from atorvastatin calcium, lactose F100, microcrystalline cellulose 102, croscarmellose sodium, thiourea and sodium stearyl fumarate. Atorvastatin calcium is a compound in new crystal form and is different from atorvastatin calcium reported in the prior art. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the description. Through tests, the compound with the new crystal form structure has obviously improved hygroscopicity, has the effect of improving the solubility of the medicine in acid media and water, has low contents of moisture and impurities and good stability and has the effects of avoiding damage of atorvastatin calcium in the acid stomach environment and reducing the occurrence rate of the side effect of myalgia. The prepared tablet has high dissolution rate and good stability.
Endometriosis affects up to 10% of all fertile women, and is associated with symptoms like infertility, dysmenorrhea, deep dyspareunia and chronic pelvic pain. 10-25% of endometriosis patients need artificial reproductive techniques (ART) to become pregnant. Endometriosis is estrogen dependent, and in theory this means, that the increased levels of estrogen during fertility treatment will worsen endometriosis symptoms. Endometriosis is a benign disease, and treatment is guided by the patient's symptoms. Worsening of endometriosis symptoms during fertility treatment may result in cessation of the treatment, operation and risk of complications.

This project will investigate worsening of symptoms in endometriosis patients undergoing artificial reproductive techniques (ART). The study compares endometriosis patients undergoing ART to two relevant reference groups; one group consisting women undergoing ART with infertility because of factors other than endometriosis, and one group consisting women with medically treated endometriosis not undergoing ART. Symptoms of endometriosis during ART will be monitored using a questionnaire that among other questions includes the validated questionnaire Endometriosis Health Profile 30® (EHP-30®). The questionnaire is administered before starting ART and later in the cycle before the patient gets to know if she is pregnant. The questionnaires as well as data collection will be administered electronically in REDCap® which is a secure web application for building and managing online surveys and databases.
PROBLEM TO BE SOLVED: To provide a method for producing the subject compound useful as an anti-diabetic agent and anti-obesity agent by reacting a specific indole compound with a specific compound. SOLUTION: This compound (X<1> is e.g. hydroxy) of formula VI is obtained by reacting a compound of formula I [R is e.g. a protecting group of a phenol hydroxy group or CH2 COX (X is e.g. a lower alkoxy)] with a compound of formula II (R<1> and R<2> are each H or a lower alkyl; R<3> is a protecting group of an amino group; and Y is a halogen), reacting the obtained compound of formula III with a reducing agent, next, (i) selectively deprotecting the protecting group of the phenol hydroxy group, reacting the resultant product with a compound of formula IV (Y<1> is an alcohol reactive residue; and X is e.g. a lower alkoxy) and selectively deprotecting the protecting group of the amino group or (ii) selectively deprotecting the protecting group of the amino group, reacting the obtained product with a compound of formula V (R<4> is e.g. a halogen) and hydrolyzing the obtained product.
After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
The invention features tobacco compositions and methods of their use and manufacture. Compositions of the invention may be based on a variety of technologies. Technologies include films, tabs, shaped parts, gels, consumable units, insoluble matrices, and hollow shapes. In addition to tobacco, compositions may also contain flavors, colors, and other additives as described herein. Compositions may also be orally disintegrable. Exemplary compositions and methods of their manufacture are described herein.
This is a randomized, double blind, placebo controlled study of intracoronary cocktail injection combined with thrombus aspiration versus thrombus aspiration alone in ST-elevation myocardial infarction patients treated with primary angioplasty. Patients with STEMI will be randomized into the cocktail group or the control group. Patients in the cocktail group will receive cocktail injection combined with thrombus aspiration. Patients in the control group will receive thrombus aspiration alone. The primary outcome of the cocktail I study is the composite of death, myocardial infarction or class IV heart failure within 1 year. The secondary outcome of the cocktail I study include slow reflow/no reflow during PCI, left ventricular function, quality of life, stroke or life-threatening bleeding within 1 year.
Chronic low back pain (cLBP) is a global health crisis that disproportionately burdens non-Hispanic Black (NHB) individuals, compared with those who identify as non-Hispanic White (NHW). Despite the growing personal and societal impact of cLBP, its biological underpinnings remain poorly understood. To elucidate the biological factors that underlie the racial disparities in cLBP, this study sought to determine whether inflammatory mediators associated with pain interference (PI), pain at rest (PAR), and movement-evoked pain (MEP) differ as a function of racial identity. Blood samples were collected from 156 individuals with cLBP (n = 98 NHB participants, n = 58 NHW participants). Enzyme-linked immunosorbent assay and multiplex assays were used to quantify concentrations of proinflammatory (fibrinogen, C-reactive protein [CRP], serum amyloid A, tumor necrosis factor α [TNF-α], and interleukin [IL]-1α, IL-1β, and IL-6) and anti-inflammatory markers (IL-4 and IL-13). Spearman rho correlations were used to assess associations among markers of inflammation and PI, PAR, and MEP using the Brief Pain Inventory-Short Form. Analyses revealed that for NHW patients, CRP, serum amyloid A, and IL-6 were positively associated with cLBP outcomes and IL-4 was inversely associated with PAR and MEP. However, for NHB patients, only IL-1α was positively associated with PAR. Our findings suggest that, while there are associations between inflammation and cLBP outcomes, the biomarkers that underlie the inflammation could very well differ as a function of racialized minority group. However, more research with racially inclusive samples is needed to elucidate the mechanisms that may contribute to racial disparities in cLBP.
The invention relates to the technical field of oral care products, in particular to an enhanced-effect oral care composition, application thereof and an oral care product containing the composition. The oral care composition includes strontium ions and casein phosphopeptide. The combined use of casein phosphopeptide and soluble strontium salt can increase the bioavailability of the strontium salt and increase the adsorption and delivery amount of strontium ions to tooth surface. The problem of system stability can be brought to the too high content of strontium ion in oral care articles for use, and this technical scheme has overcome the effect that strontium ion is not ideal because of being difficult to further promote the concentration and bring in oral care articles for use technical problem. And the casein phosphopeptide and the strontium can simultaneously exert the effect of resisting the acid erosion of the teeth in a synergistic way, and the remineralization capability of the teeth is improved. The composition of the technical scheme can improve the effects of the oral care product on dentin sensitivity and tooth erosion, and the product containing the composition has good safety and ideal application and popularization values.
The invention belongs to the technical field of medicinal materials and preparation thereof, and discloses a preparation for treating liver cirrhosis and a preparation method thereof. The preparation is prepared by mixing conventional medicinal materials with abundant resources and suitable drug effect with various fruits rich in vitamins. The raw materials in the preparation are matched, and the effects of mutual assistance and mutual fusion of the raw materials are obviously enhanced, so that the effects of soothing liver, dissipating qi, regulating liver, tonifying qi, tonifying liver and kidney, promoting blood circulation, diminishing swelling, soothing liver and moistening liver are achieved. Meanwhile, under the action of effective cooperation of various raw materials, the curative ratio is obviously improved, and the traditional Chinese medicine has extremely high curative effect on treating the cirrhosis. The preparation method of the preparation protects the effective and applicable components of various raw materials, and has the advantages of simple operation process, less operation equipment, low requirement on operators and low cost. The preparation is safe and reliable, has no toxic and side effects, retains the principle of maintaining ecological balance during the collection process of various raw materials, and is suitable for individuals of all ages.
FIELD: pharmacy. SUBSTANCE: invention relates to microspheres used as vector-particles designated for transporting biologically active substances, especially hydrophilic substances (peptides and proteins) for oral administration. Microspheres are formed by continuous network made of a polymeric material-carrier based on polymethylmethylidenemalonate. Biologically active substance can be dispersed in a material-carrier. Continuous network shows dense properties or can include globules with an aqueous phase distributed in its. Microspheres are prepared by the double emulsification method. Microspheres exhibit progressing and modulating decomposition kinetics and provides to carry out incapsulating hydrophilic substances of biological origin with the enhanced effectiveness and provide delivery of indicated substance to required body site also. EFFECT: improved preparing method, valuable properties of microspheres. 14 cl
The invention discloses Frullania tamarisci (L.) Dum. heart-fire-clearing and restless-relieving soup stock and a production method thereof. The Frullania tamarisci (L.) Dum. heart-fire-clearing and restless-relieving soup stock is prepared from the following raw materials: Frullania tamarisci (L.) Dum., short greenbrier roots, Zornia gibbosa, Nepal pearleverlasting herb, multi-spike tanoak leaves, Salvia lankongensis C. Y. Wu., Drilgrass, golden sealavender flowers, dahurian angelica roots, pogonatherum paniceum, faenum graecum and so on. The production method specifically comprises the following steps: step 1, selecting the raw materials, then drying and sterilizing the selected raw materials; step 2, mixing and crushing the raw materials; step 3, decocting the mixed and crushed raw materials twice and extracting the filtrates of the two decoctions; step 4, concentrating the extracted filtrates in vacuum to obtain concentrated solutions, then mixing the two concentrated solutions; step 5, drying the mixed concentrated solution, then crushing the dried mixture; and step 6, bagging the crushed dried mixture and sterilizing to obtain the final product. The drug efficacies of the medicines are synergized in the Frullania tamarisci (L.) Dum. heart-fire-clearing and restless-relieving soup stock disclosed by the invention, so that the effects of the Frullania tamarisci (L.) Dum. heart-fire-clearing and restless-relieving soup stock can be achieved; moreover, the Frullania tamarisci (L.) Dum. heart-fire-clearing and restless-relieving soup stock has the functions of clearing away heart fire, relieving restless, tranquilizing the mind, alleviating mental depression, nourishing the heat and supplementing Qi in long-term use.
This is a mixed methods study. The investigators will collect qualitative data from participants by conducting 1-2 hour semi-structured interviews on Zoom. The interview questions are designed to systemically inquire about patient experiences, affective reactions, coping strategies, social support, self-identity issues, and treatment experiences. The investigators will collect quantitative data by asking participants to complete The Brief Illness Perception Questionnaire. The data will be analyzed using a comprehensive stress and coping model, which has not been done previously in the field. The investigators hope to discover themes about psychosocial burdens and related coping mechanisms.
OBJECTIVES: I. Compare the efficacy of itraconazole versus fluconazole in reducing the incidence of breakthrough Aspergillus infections in patients undergoing allogeneic peripheral blood stem cell or bone marrow transplantation. II. Compare the incidence of combined mold/yeast infections and the use of alternative systemic antifungal treatments in these patients on this regimen. III. Compare the toxic effects of these two drugs in these patients. IV. Determine the survival rate of these patients.

OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms. Arm I: Patients receive fluconazole orally or IV daily beginning at start of conditioning regimen and continuing until day 180 or until 4 weeks after stopping corticosteroids (if it occurs between days 120-180). Arm II: Patients receive oral fluconazole daily beginning at start of conditioning regimen and continuing until day 0. Patients then receive itraconazole orally or IV daily beginning on day 0 and continuing until day 180, or until 4 weeks after stopping corticosteroids (if it occurs between days 120-180).

PROJECTED ACCRUAL: A total of 578 patients (289 per arm) will be accrued for this study within 4 years.
Acute pancreatitis (AP) can lead to death; however, there is no specific treatment for AP. Screening of drugs for AP treatment is rarely performed. Compounds were screened in a primary pancreatic acinar cell and peritoneal macrophage coculture system. Compounds were used in vitro and in vivo. Compound targets were predicted and validated. Among the 18 nitrogen-containing heterocycles, Z10 was shown to decrease the cerulein plus lipopolysaccharide (CL)-induced secretion of both acinar digestive enzymes and macrophage cytokines. Z10 was also shown to ameliorate CL-induced or sodium taurocholate-induced AP in mice. Proteomics analysis and enzyme linked immunosorbent assay (ELISA) revealed that Z10 decreased the levels of D-dopachrome tautomerase (Ddt) within macrophages and those in the extracellular milieu under CL treatment. Z10 also decreased Ddt expression in AP mice. Moreover, exogenous Ddt induced cytokine and digestive enzyme secretion, which could be inhibited by Z10. Ddt knockdown inhibited CL-induced cytokine secretion. Medium from CL-treated macrophages induced the release of amylase by acinar cells, and Ddt knockdown medium decreased amylase secretion. The target of Z10 was predicted to be ERK2. Z10 increased the thermostability of ERK1/2 but not ERK1 K72A/ERK2 K52A. The docking poses of ERK1 and ERK2 with Z10 were similar. Z10 inhibited ERK1/2 phosphorylation, and Ddt levels and cytokines were regulated by ERK1/2 during AP. Additionally, Z10 could not further inhibit cytokines under ERK1/2 knockdown with CL. Thus, this study revealed that Z10-mediated ERK1/2 inhibition decreased Ddt expression and secretion by macrophages. Ddt inhibition decreased cytokine release and digestive enzyme secretion.
Early diagnosis and appropriate management of Cesarean scar pregnancy (CSP) are crucial to prevent severe complications, such as uterine rupture, severe hemorrhage and placenta accreta spectrum disorders. In this article, we provide a step-by-step tutorial for the standardized sonographic evaluation of CSP in the first trimester. Practical steps for performing a standardized transvaginal ultrasound examination to diagnose CSP are outlined, focusing on criteria and techniques essential for accurate identification and classification. Key sonographic markers, including gestational sac location, cardiac activity, placental implantation and myometrial thickness, are detailed. The evaluation process is presented according to assessment of the uterine scar, differential diagnosis, detailed CSP evaluation and CSP classification. This step-by-step tutorial emphasizes the importance of scanning in two planes (sagittal and transverse), utilizing color or power Doppler and differentiating CSP from other low-lying pregnancies. The CSP classification is described in detail and is based on the location of the largest part of the gestational sac relative to the uterine cavity and serosal lines. This descriptive classification is recommended for clinical use to stimulate uniform description and evaluation. Such a standardized sonographic evaluation of CSP in the first trimester is essential for early diagnosis and management, helping to prevent life-threatening complications and to preserve fertility. Training sonographers in detailed evaluation techniques and promoting awareness of CSP are critical. The structured approach to CSP diagnosis presented herein is supported by a free e-learning course available online. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
To prevent a suppository from dropping due to intestine and vaginal contraction or ejection of a body gas.SOLUTION: A suppository capsule material includes a tip tetra-part 12 serving as an insertion side and a columnar cylindrical part 15 continuously installed in a rear end of the tip tetra-part. The suppository capsule material is assumed as a technical premise, and a direction operation part 17 with a spherical surface is provided in the rear end of the columnar cylindrical part 15 (claim 1). By providing the direction operation part with the spherical surface, when the direction operation part positioned in the rear end is pushed in an appropriate direction of top/bottom and left/right directions in the insertion of the suppository, the spherical surface of the suppository capsule material slides between a body wall surface and itself, and the capsule material is turned. When the capsule material is turned to the insertion direction, the suppository can take a sideways-facing posture in the intestine or the vagina. While the tip surface of the tip tetra-part of the insertion side and the rear end surface of the direction operation part are brought into contact with the internal wall, the suppository capsule material is made to stay and is maintained. A contact pressure with the internal wall is high, and therefore dropping and the like are prevented from being caused in normal use.SELECTED DRAWING: Figure 1